EPISODE · Aug 27, 2018 · 10 MIN
CEO Dr. Nader Pourhassan of CytoDyn Inc. (OTCQB: CYDY)
from Stock Day Media · host Stock Day Media
CEO Dr. Nader Pourhassan of CytoDyn Inc. (OTCQB: CYDY), joins the Show to discuss recent Phase 3 trials and results of PRO140 monotherapy for the chronic suppression of HIV. OTCQB: CYDY # PRO 140 # HIV/AIDS therapeutics # biotechnology company # Colon Cancer # less frequent dosing # minimal side effects # protects healthy cells # treatment and prevention of HIV # humanized monoclonal antibodies Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy
What this episode covers
CEO Dr. Nader Pourhassan of CytoDyn Inc. (OTCQB: CYDY), joins the Show to discuss recent Phase 3 trials and results of PRO140 monotherapy for the chronic suppression of HIV. OTCQB: CYDY # PRO 140 # HIV/AIDS therapeutics # biotechnology company # Colon Cancer # less frequent dosing # minimal side effects # protects healthy cells # treatment and prevention of HIV # humanized monoclonal antibodies Advertising Inquiries: https://redcircle.com/brands Privacy & Opt-Out: https://redcircle.com/privacy
NOW PLAYING
CEO Dr. Nader Pourhassan of CytoDyn Inc. (OTCQB: CYDY)
No transcript for this episode yet
Similar Episodes
Sep 22, 2023 ·20m
Sep 22, 2023 ·20m
Sep 22, 2023 ·27m
Sep 22, 2023 ·14m
Sep 22, 2023 ·24m
Sep 22, 2023 ·22m